Clinical Trial

Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer

Name: Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer — clinical trial record (NCT07635290)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study aims to evaluate the safety and preliminary efficacy of anlotinib combined with cadonilimab and PULSAR in previously treated advanced unresectable or netastatic biliary tract cancer.

Trial Details

NCT Number	NCT07635290
Lead Sponsor	West China Hospital Collaborators: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Akeso
Conditions	Previously Treated, Advanced, Biliary Tract Cancers
Enrollment	26 participants
Start Date	2026-06-03
Primary Completion	2027-06-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-09